Rapid Micro Biosystems (RPID) Earnings Date & Reports

Key Takeaways

• Rapid Micro Biosystems is expected to report its third quarter 2026 results on or around November 5, 2026.
• Analyst consensus points to third-quarter revenue near $10.1 million and a net loss of roughly $0.20 per share, above the company's guidance of at least $9.5 million in revenue.
• Management has guided for third-quarter gross margin of at least 20%, building on the record 15% reported in the second quarter of 2026.
• Investors will closely watch Growth Direct system placements (at least seven guided for the quarter) and the pace of recurring revenue growth from consumables and service contracts.
• Full-year 2026 revenue guidance of $37 million to $41 million was reaffirmed, with 30 to 38 system placements expected.
• For more on RPID's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to see the strategies gaining traction among traders right now.

Earnings Context and Why It Matters

Rapid Micro Biosystems sells automated microbial quality control (QC) systems used in pharmaceutical manufacturing, led by its Growth Direct platform. Because the company is still scaling toward profitability, each quarterly report is scrutinized for two signals: the pace of system placements and the expansion of recurring revenue from consumables and service contracts. In the second quarter of 2026, the company placed four systems, reached its 200th installed system, and lifted gross margin to a record 15%. A five-year global distribution agreement with MilliporeSigma has broadened commercial reach. With the company targeting gross margins above 50% and positive cash flow by the end of 2028, the third-quarter print serves as a key checkpoint on that trajectory.

Earnings Expectations

Wall Street consensus for the third quarter of 2026 calls for revenue of approximately $10.1 million and a net loss of about $0.20 per share (EPS, or earnings per share). That compares with company guidance for at least $9.5 million in revenue and at least seven Growth Direct system placements, with gross margin expected at 20% or better. Full-year 2026 guidance remains $37 million to $41 million in revenue, 30 to 38 system placements, at least 27 system validations, and a gross margin of roughly 20%.

Historically, RPID's stock has reacted sharply around earnings. After the first quarter of 2026, shares rose about 5% even though the company missed EPS expectations. The second-quarter 2026 report triggered a decline of roughly 17%, underscoring how sensitive the stock is to margin commentary and placement detail rather than headline results alone.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Rapid Micro Biosystems, it offers a faster way to identify setups across the market.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is cautious but focused on execution. The stock's sharp pullback after the second-quarter release reflected investor sensitivity to the pace of margin improvement and placement activity, even as revenue and gross margin both advanced. Heading into this print, the key question is whether the company can convert its guided 20%-plus gross margin and sequential revenue step-up into renewed confidence. Risks include lumpy system placement timing, customer concentration, and ongoing operating losses, all of which could weigh on the share price if results or guidance disappoint.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors will be watching whether recurring revenue keeps growing as a share of the total. In recent quarters, consumables and service contracts have represented more than 60% of revenue, providing a more predictable base than one-time system sales. Sustained growth here is central to the company's path toward its long-term gross margin goal of 50% or more.

The MilliporeSigma distribution partnership is another factor to monitor. Management has indicated it expects the collaboration to contribute more meaningfully in the second half of 2026 and into 2027, potentially accelerating placements and lowering costs through supply chain and sourcing improvements.

Finally, investors should track the company's liquidity runway and cost discipline. Rapid Micro Biosystems ended the second quarter of 2026 with roughly $20 million in cash and investments, and management announced August 2026 cost-reduction actions expected to generate about $3 million in annual savings beginning in 2027. Progress on cash burn, along with any updates to full-year or 2028 targets, will likely shape the stock's next move.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations